Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8910 results

  1. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 24 February 2026.

    Health technology evaluation
    In consultation

  2. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

    Health technology evaluations
    In development

  4. Surgical mesh for treatment of non-primary ventral hernias

    Awaiting development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  10. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

    Interventional procedures guidance
    In development

  11. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]

    Awaiting development Reference number: GID-TA11945 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

    Health technology evaluations
    In development

  14. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  15. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

    Topic prioritisation

    Highly specialised technologies guidance
    Topic prioritisation